The UCB acquisition strategy's superiority over EI in high-uncertainty drug-discovery landscapes (validated across 6/6 targets) will transfer to MSH3 Walker-A pocket screening when an unrelated P-loop ATPase counter-screen (adenylate kinase) is embedded as a hard constraint in the Bayesian optimisation objective, enabling discovery of genuinely MSH3-selective compounds by penalising candidates whose predicted affinity for 1AKE equals or exceeds their MSH3 score, directly addressing CHDI's off-target selectivity liability.
Adversarial Debate Score
50% survival rate under critique
Expert panel critique
Independent views, each critiquing the hypothesis on its own — the score rewards genuine disagreement and discounts consensus.
The strict critic was recused on this topic; an adversarial reviewer stood in to keep scrutiny intact.
Supporting Research Papers
- DBMol: Design of High-Affinity, Target-Specific Small Molecules through Structure Prediction Models
Designing small molecule ligands that bind with high affinity to specific protein pockets is a fundamental goal in drug discovery, as small molecules constitute a major fraction of approved therapeuti...
- Identification of a small molecule inhibitor of Ebola virus genome replication and transcription using in silico screening
ABSTRACT Ebola virus (EBOV) causes a severe haemorrhagic fever in humans and has a mortality rate over 50%. With no licensed drug treatments available, EBOV poses a significant threat. Investigations ...
- Budget-Sensitive Discovery Scoring: A Formally Verified Framework for Evaluating AI-Guided Scientific Selection
Scientific discovery increasingly relies on AI systems to select candidates for expensive experimental validation, yet no principled, budget-aware evaluation framework exists for comparing selection s...
- Empowering Chemical Structures with Biological Insights for Scalable Phenotypic Virtual Screening
Motivation: The scalable identification of bioactive compounds is essential for contemporary drug discovery. This process faces a key trade-off: structural screening offers scalability but lacks biolo...
- AMPBench-MT: A Homology-Controlled Benchmark for Antimicrobial Peptide Potency, Spectrum, and Safety Prediction
Computational AMP discovery is often evaluated through AMP/non-AMP recognition, yet follow-up decisions depend on assay-derived evidence such as target-species potency, hemolysis, toxicity, and select...
Formal Verification
Z3 checks whether the hypothesis is internally consistent, not whether it is empirically true.